![Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes - ScienceDirect Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1549963418305501-ga1.jpg)
Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes - ScienceDirect
![Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes - ScienceDirect Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168365920301218-ga1.jpg)
Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes - ScienceDirect
![Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?) | Nature Reviews Endocrinology Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?) | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41574-020-00443-4/MediaObjects/41574_2020_443_Fig1_HTML.png)
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?) | Nature Reviews Endocrinology
![The challenge of modulating β-cell autoimmunity in type 1 diabetes - The Lancet Diabetes & Endocrinology The challenge of modulating β-cell autoimmunity in type 1 diabetes - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/e9aa8289-e280-4705-9f0a-d5a4c61f74d6/gr1_lrg.jpg)
The challenge of modulating β-cell autoimmunity in type 1 diabetes - The Lancet Diabetes & Endocrinology
![Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes | Nature Reviews Immunology Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes | Nature Reviews Immunology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnri2705/MediaObjects/41577_2010_Article_BFnri2705_Fig1_HTML.jpg)
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes | Nature Reviews Immunology
![Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process? - ScienceDirect Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S155041311630540X-fx1.jpg)
Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process? - ScienceDirect
![Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes](https://pub.mdpi-res.com/diabetology/diabetology-03-00007/article_deploy/html/images/diabetology-03-00007-g001.png?1644221977)
Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
![Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes](https://pub.mdpi-res.com/diabetology/diabetology-03-00007/article_deploy/html/images/diabetology-03-00007-g002.png?1644221977)